nanotech-investing Soleno Therapeutics Announces Select Preliminary Fourth Quarter and Full-Year 2025 Results
nanotech-investing Soleno Therapeutics Announces Publication of Results from Pivotal Study of VYKAT XR in the Journal of Clinical Endocrinology and Metabolism
nanotech-investing Soleno Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
nanotech-investing Soleno Therapeutics Announces Entry Into $100 Million Accelerated Share Repurchase Agreement
nanotech-investing Soleno Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on U.S. Launch of VYKAT XR
nanotech-investing Soleno Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025, at 4:30 PM ET
nanotech-investing Soleno Therapeutics Appoints Biopharmaceutical Executive Mark W. Hahn to its Board of Directors
